Evaluation of sensitivity of different organisms to cefepime and tazobactum (Megapime XP) in comparison to cefepime and ceftazidime

Journal of the Indian Medical Association

Volumn 106, Issue 9, 2008, Pages 605-611

  Pal, R B ^a,b   Pal, Paramita ^a,b   Venkatesh, Veena ^a   Kulkarni, K P ^a  

^a Alkem Laboratories Limited   (India)

^b EOS Laboratories   (United States)

Author keywords

Cefepime; Ceftazidime; Clinical and Laboratory Standard Institute (CLSI); Kirby Bauer disc diffusion method; Tazobactum

Indexed keywords

CEFEPIME; CEFTAZIDIME; TAZOBACTAM;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CELL STRUCTURE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; ENTEROBACTER; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROTEUS; PSEUDOMONAS AERUGINOSA; SALMONELLA; STAPHYLOCOCCUS;

EID: 60549112244     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Amyes SGB, Miles RS - Extended-spectrum β-lactamases- the role of inhibitors in therapy. J Antimicrobial Chemother 1998; 42: 415-7.
2. Burgess DS, Hastings RW, Hardin TC - Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther 2000; 22: 66-75.